Cited 0 times in
PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김종찬 | - |
dc.contributor.author | 장원식 | - |
dc.contributor.author | 정민선 | - |
dc.contributor.author | 함원식 | - |
dc.date.accessioned | 2024-03-22T06:50:25Z | - |
dc.date.available | 2024-03-22T06:50:25Z | - |
dc.date.issued | 2024-01 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198632 | - |
dc.description.abstract | Background: Although a combination of immune checkpoint inhibitors (ICIs) is recommended as the first line treatment option for metastatic renal cell carcinoma (mRCC), several immune-related adverse events (irAEs) occur, especially hepatitis. We explored the therapeutic benefits and safety profile of combining oncolytic vaccinia virus, JX-594, with a programmed cell death protein-1 (PD-1) inhibitor. Methods: We used early-stage and advanced-stage orthotopic murine mRCC models developed by our group. PD-1 inhibitor monotherapy or a PD-1 inhibitor combined with either JX-594 or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor were systemically injected through the peritoneum. An immunofluorescence analysis was performed to analyze the tumor immune microenvironment (TIME). irAEs were assessed in terms of hepatitis. Results: In the early-stage mRCC model mice, the combination of JX-594 and a PD-1 inhibitor significantly decreased the primary tumor size and number of lung nodules, compared with the ICI combination, but the JX-594 and PD-1 inhibitor combination and ICI combination did not differ significantly in the advanced-stage mRCC model mice. The JX-594 and PD-1 inhibitor combination induced tumor-suppressing TIME changes in both the early- and advanced-stage mRCC models. Furthermore, mice treated with the ICI combination had significantly greater hepatic injuries than those treated with the JX-594 and PD-1 inhibitor combination which was evaluated in early-stage mRCC model. Conclusions: The JX-594 and PD-1 inhibitor combination effectively reduced primary tumors and the metastatic burden, similar to ICI combination therapy, through dynamic remodeling of the TIME. Furthermore, hepatitis was significantly decreased in the JX-594 and PD-1 inhibitor combination group, suggesting the potential benefit of that combination for reducing ICI-induced toxicity. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | CANCER CELL INTERNATIONAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.googleauthor | Jee Soo Park | - |
dc.contributor.googleauthor | Myung Eun Lee | - |
dc.contributor.googleauthor | Jongchan Kim | - |
dc.contributor.googleauthor | Keunhee Oh | - |
dc.contributor.googleauthor | Namhee Lee | - |
dc.contributor.googleauthor | Minsun Jung | - |
dc.contributor.googleauthor | Won Sik Jang | - |
dc.contributor.googleauthor | Won Sik Ham | - |
dc.identifier.doi | 10.1186/s12935-024-03238-z | - |
dc.contributor.localId | A04541 | - |
dc.contributor.localId | A05268 | - |
dc.contributor.localId | A06280 | - |
dc.contributor.localId | A04337 | - |
dc.relation.journalcode | J00436 | - |
dc.identifier.eissn | 1475-2867 | - |
dc.identifier.pmid | 38291394 | - |
dc.subject.keyword | Hepatitis | - |
dc.subject.keyword | Immune-related adverse events | - |
dc.subject.keyword | Immunotherapy | - |
dc.subject.keyword | Oncolytic viruses | - |
dc.subject.keyword | Renal cell carcinoma | - |
dc.contributor.alternativeName | Kim, Jong Chan | - |
dc.contributor.affiliatedAuthor | 김종찬 | - |
dc.contributor.affiliatedAuthor | 장원식 | - |
dc.contributor.affiliatedAuthor | 정민선 | - |
dc.contributor.affiliatedAuthor | 함원식 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 11 | - |
dc.identifier.bibliographicCitation | CANCER CELL INTERNATIONAL, Vol.24(1) : 1-11, 2024-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.